Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Satralizumab monotherapy reduces NMOSD relapse rate

Publish date:: May 14, 2020

Key clinical point: Satralizumab monotherapy reduces the rate of neuromyelitis optica spectrum disorder relapse, compared with placebo.

Major finding: The proportion of patients who relapsed was smaller among patients who received satralizumab, compared with patients who received placebo (30% vs. 50%). The hazard ratio was 0.45.

Study details: A randomized, double-blind, placebo-controlled phase 3 trial that enrolled 95 patients with neuromyelitis optica spectrum disorder.

Disclosures: SakuraStar was funded by Chugai Pharmaceutical, a member of the Roche group. Authors reported grants, personal fees, and nonfinancial support from Chugai Pharmaceutical, and several coauthors were employees of Chugai Pharmaceutical.

Citation:

Traboulsee A et al. Lancet Neurol. 2020;19(5):402-12.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Multiple Sclerosis

Long-term safety and efficacy of teriflunomide for relapsing MS,

Newer DMTs are more effective than injectable DMTs in pediatric MS,

Neutrophil granulocyte markers may distinguish between demyelinating diseases,

Bacteria may be associated with risk of MS relapse,

Women with MS may have increased subclinical disease activity during pregnancy,